Bristol Myers Squibb (BMY) Cash & Equivalents (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash & Equivalents for 18 consecutive years, with $8.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 30.77% year-over-year to $8.7 billion in Q2 2026; TTM through Jun 2026 was $8.7 billion, a 30.77% decrease from a year earlier, with the FY2025 full-year figure at $10.2 billion, down 1.32% from the prior year.
• Cash & Equivalents was $8.7 billion for Q2 2026 at Bristol Myers Squibb, down from $9.6 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.7 billion in Q3 2025 and troughed at $6.3 billion in Q2 2024.
• A 5-year average of $9.9 billion and a median of $9.5 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 42.88% in 2022 and soared 100.21% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $9.1 billion in 2022, then increased by 25.66% to $11.5 billion in 2023, then dropped by 9.75% to $10.3 billion in 2024, then decreased by 1.32% to $10.2 billion in 2025, then retreated by 14.57% to $8.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $8.7 billion (Q2 2026), $9.6 billion (Q1 2026), and $10.2 billion (Q4 2025), per Business Quant data.